NEW YORK, Dec. 28, 2017 /PRNewswire/ -- PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2026Read the full report: https://www.reportlinker.com/p05257608
SummaryInflammatory bowel disease (IBD) refers to two chronic autoimmune diseases that cause intestinal inflammation: Crohn's disease (CD) and ulcerative colitis (UC). In CD, chronic inflammation may affect any part of the gastrointestinal (GI) tract from the mouth to the anal area. However, CD occurs most commonly in the lower part of the small intestine (ileum) and in the large intestine. The disease also may affect only some segments of the intestinal tract while leaving normal segments between the affected areas.In 2016, it is estimated that the global CD market was valued at over US$9 billion across the 7MM. By the end of the forecast period in 2026, sales across these markets will have grown steadily to reach almost US$13.5 billion, representing a Compound Annual Growth Rate (CAGR) of around 3.8% over the 10-year timeframe, which includes six new market entrants and the launch of biosimilars.Major growth drivers in the CD market over the forecast period include -- The anticipated launches of interleukin (IL) inhibitors and anti-integrin therapies, including AbbVie's risankizumab, Genentech's etrolizumab, and Takeda's subcutaneous Entyvio (Entyvio SC), as well as Galapagos/Gilead's filgotinib, Celgene's mongersen sodium, and Shire's SHP-647, will provide more treatment options for physicians to choose from.- The number of diagnosed prevalent CD cases will increase to over 1.8 million in 2026 at an annual growth rate (AGR) of 2.3%. Total treated cases will grow to almost 1.2 million at an AGR of 2.3% during the 10-year period of 2016-2026.- Strong uptake of J&J's IL-12/23 inhibitor Stelarawill continue, generating sales of about US$1.2 billion across the 7MM in 2026.- The high unmet need for improved medical management of perianal fistulas presents an untapped market opportunity.The report "PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2026", providesoverview of CD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.In depth, this report provides the following -- Topline CD market revenue from 2016-2026. ACOT and major pipeline product sales in this forecast period are included.- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting CD therapeutics sales in the 7MM.- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.- Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.Scope- Overview of CD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.- Topline CD market revenue from 2016-2026. ACOT and major pipeline product sales in this forecast period are included.- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting CD therapeutics sales in the 7MM.- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.- Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.Reasons to buyThe report will enable you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CD therapeutics market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.Read the full report: https://www.reportlinker.com/p05257608
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected]
US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/pharmapoint-crohns-disease---global-drug-forecast-and-market-analysis-to-2026-300575853.html
SOURCE Reportlinker
